Hepion Pharmaceuticals

Update in progress

HEPA (OTC Markets OTCQB)

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focusing on therapies for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a cyclophilin inhibitor in preclinical studies, aiming to reduce liver fibrosis and inflammation, liver tumor burden, and viral titers (HBV, HCV, HDV). Formerly ContraVir, it adopted the Hepion name in 2019. Founded in 2013, it is headquartered in Morristown, New Jersey.